CONCORD, Calif.--(BUSINESS WIRE)--
Cerus Corporation (Nasdaq: CERS) today announced Dr. Laurence Corash,
the Company’s co-founder and chief scientific officer has been awarded
the prestigious Dale A. Smith Memorial Award by AABB’s National Blood
Foundation.
The award, which was created in 2002, honors Dale A. Smith, a long-time
Baxter Health executive who was responsible for establishing the Fenwal
Division. The award is presented to individuals or organizations in
recognition of groundbreaking work in utilizing technology for
innovation in transfusion medicine or cellular therapies. The 2018 award
is in acknowledgement of Dr. Corash’s role in developing pathogen
reduction technology to prevent transfusion-transmitted infection and
other complications of blood transfusion.
“I am honored to be selected as the 2018 award recipient,” said Dr.
Laurence Corash. “My endeavors would not have been possible had it not
been for the tireless efforts by Cerus’ employees and research
collaborations with numerous clinicians and scientists in the US,
Europe, and the Middle East. It is especially gratifying to see this
technology move from the research laboratory to routine use in over 200
blood centers. Since introduction of this technology into routine use,
blood centers have used INTERCEPT Blood System sets to produce more than
5 million pathogen-reduced blood components which have improved patient
safety meaningfully.”
“This award is particularly meaningful because Dale Smith was a mentor
to me,” continued Corash. “When I co-founded Cerus to develop
pathogen-reduction technology, we formed a partnership with Baxter and
Dale joined our Board of Directors.”
Corash will be presented the Dale A. Smith Memorial Award during the
2018 Annual AABB meeting which is being held in Boston between October 13th
and 16th.
ABOUT CERUS
Cerus Corporation is a biomedical products company focused in the field
of blood transfusion safety. The INTERCEPT Blood System is designed to
reduce the risk of transfusion-transmitted infections by inactivating a
broad range of pathogens such as viruses, bacteria and parasites that
may be present in donated blood. The nucleic acid targeting mechanism of
action of the INTERCEPT treatment is designed to inactivate established
transfusion threats, such as hepatitis B and C, HIV, West Nile virus and
bacteria, as well as emerging pathogens such as chikungunya, malaria and
dengue. Cerus currently markets and sells the INTERCEPT Blood System for
both platelets and plasma in the United States, Europe, the Commonwealth
of Independent States, the Middle East and selected countries in other
regions around the world. The INTERCEPT Red Blood Cell system is in
clinical development. See http://www.cerus.com
for information about Cerus.
INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus
Corporation.
View source version on businesswire.com:
https://www.businesswire.com/news/home/20181011005208/en/
Cerus Corporation
Tim Lee, 925-288-6137
Investor Relations
Director
Source: Cerus Corporation